Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Clinical Pharmacology : Advances and Applications|August 14, 2012
Management of antipsychotic treatment discontinuation and interruptions using model-based simulationsMahesh N Samtani, John J Sheehan, Dong-Jing Fu, et al.
Neuropsychiatric Disease and Treatment|March 16, 2013
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsLarry Alphs, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
Psychiatry Research|October 17, 2020
Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide AssessmentLarry Alphs, Dong-Jing Fu, David Williamson, et al.
Psychiatric Research and Clinical Practice|September 14, 2022
Economic Burden of Treatment-Resistant Depression Among Patients Hospitalized for Major Depressive Disorder in the United StatesJay Lin, Holly Szukis, John J Sheehan, et al.
Current Drug Safety|November 5, 2010
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databasesLarry Alphs, Srihari Gopal, Keith Karcher, et al.
International Clinical Psychopharmacology|March 15, 2016
Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapyLarry Alphs, Henry A Nasrallah, Cynthia A Bossie, et al.
International Clinical Psychopharmacology|March 11, 2010
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidoneCarla M Canuso, Augusto Grinspan, Amir Kalali, et al.
Journal of Medical Economics|August 28, 2010
Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventionsJ Thomas Haskins, Wayne Macfadden, Norris Turner, et al.
Journal of Medical Economics|April 9, 2015
Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvementErik Muser, Chris M Kozma, Carmela J Benson, et al.
Bipolar Disorders|November 20, 2009
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequentlyWayne Macfadden, Larry Alphs, J Thomas Haskins, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Clinical Pharmacology : Advances and Applications|August 14, 2012
Management of antipsychotic treatment discontinuation and interruptions using model-based simulationsMahesh N Samtani, John J Sheehan, Dong-Jing Fu, et al.
Neuropsychiatric Disease and Treatment|March 16, 2013
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsLarry Alphs, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
Psychiatry Research|October 17, 2020
Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide AssessmentLarry Alphs, Dong-Jing Fu, David Williamson, et al.
Psychiatric Research and Clinical Practice|September 14, 2022
Economic Burden of Treatment-Resistant Depression Among Patients Hospitalized for Major Depressive Disorder in the United StatesJay Lin, Holly Szukis, John J Sheehan, et al.
Current Drug Safety|November 5, 2010
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databasesLarry Alphs, Srihari Gopal, Keith Karcher, et al.
International Clinical Psychopharmacology|March 15, 2016
Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapyLarry Alphs, Henry A Nasrallah, Cynthia A Bossie, et al.
International Clinical Psychopharmacology|March 11, 2010
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidoneCarla M Canuso, Augusto Grinspan, Amir Kalali, et al.
Journal of Medical Economics|August 28, 2010
Clinical characteristics and resource utilization of patients with bipolar disorder who have frequent psychiatric interventionsJ Thomas Haskins, Wayne Macfadden, Norris Turner, et al.
Journal of Medical Economics|April 9, 2015
Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvementErik Muser, Chris M Kozma, Carmela J Benson, et al.
Bipolar Disorders|November 20, 2009
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequentlyWayne Macfadden, Larry Alphs, J Thomas Haskins, et al.
Pageof 12